Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
about
Bilateral angle-closure glaucoma in a young female receiving cabergoline: a case reportPituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.Effect of dopaminergic drug treatment on surgical findings in prolactinomas.Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.Recurrence of hyperprolactinemia following dopamine agonist withdrawal and possible predictive factors of recurrence in prolactinomas.
P2860
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@en
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@nl
type
label
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@en
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@nl
prefLabel
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@en
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@nl
P2093
P2860
P356
P1476
Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
@en
P2093
Karim Serri
Omar Serri
Sophie Vallette
P2860
P356
10.1586/ERC.09.167
P577
2010-01-01T00:00:00Z